Herbal medicines for liver diseases

Digestive Diseases and Sciences

Volumn 50, Issue 10, 2005, Pages 1807-1812

  Dhiman, Radha K ^a   Chawla, Yogesh K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Complementary and alternative medicine; Glycyrrhizin; Hebal products; Hepatoprotective agent; Liv 52; Milk thistle; Phyllanthus; Silybum marianum; Stronger neominophagen C

Indexed keywords

AYURVEDIC DRUG; CARDIAC GLYCOSIDE; GLYCYRRHIZA EXTRACT; INTERFERON; LIV 52; NEOMINOPHAGEN C; PHYLLANTHUS AMARUS EXTRACT; SILYBUM MARIANUM EXTRACT;

ANTIINFLAMMATORY ACTIVITY; ASCITES; CANCER SURVIVAL; CELL PROTECTION; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; GLYCYRRHIZA; HEPATITIS B; HEPATITIS C; HERBAL MEDICINE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER PROTECTION; MORTALITY; NONHUMAN; PHYLLANTHUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SILYBUM MARIANUM; SODIUM RETENTION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; DRUG COMBINATIONS; GLYCYRRHIZIC ACID; HUMANS; LIVER DISEASES; PHYLLANTHUS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PREPARATIONS; SILYMARIN;

EID: 26244435620     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2942-9     Document Type: Review

References (52)

1. Thyagrajan SP, Jayaram S, Gopalakrishnan V, Han R, Jayakumar P, Sripathi MS: Herbal medicines for liver diseases in India. J Gastroenterol Hepatol 17:S370-S376, 2002
2. Schuppan D, Jia J-D, Brinkhaus B, Hahn EG: Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 30:1099-1104, 1999
3. Dhiman RK: Herbal hepatoprotective agents: marketing gimmick or potential therapies? Trop Gastroenterol 24:160-162, 2003
4. Woolf SH, Sox HC Jr: The Expert Panel on Preventive Services: continuing the work of the U.S.Preventive Services Task Force. Am J Prev Med 7:326-330, 1991
5. Venkateswaran PS, Millman I, Blumberg BS: Effects of an abstract of Phyllanthus niuri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Proc Natl Acad Sci USA 84:274-278, 1987
6. Ott M, Thayagrajan SP, Gupta S: Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur J Clin Invest 27:908-915, 1997
7. Lee CD, Ott M, Thyagarajan SP, Sharfritz DA, Burk RD, Gupta S: Phyllanthus amarus down regulates hepatitis B virus mRNA transcription and replication. Eur J Clin Invest 24:161-168, 1996
8. Polya GM, Wang BH, Foo LY: Inhibition of signal regulated protein kinases by plant derived hydrolyzable tannins. Phytochemistry 38:307-314, 1995
9. Thyagarajan SP, Subramanian S, Thirunaksundari T, Venkateswaran PS, Blumberg BS: Effects of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 2:764-766, 1988
10. Thyagrajan SP, Jayaram S, Valliammae T, Madangopalan N, Pal VG, Jayaraman K: Phyllanthus amarus and hepatitis B. Lancet 336:949-950, 1990
11. Thyagarajan SP, Jayaram S, Panneeselvam A, et al.: Effect of Phyllanthus amarus, an Indian medicinal plant on healthy carriers of hepatitis B virus. Results of six clinical trials. Indian J Gastroenterol 18 (Suppl 1):S26, 1999 (abstr)
12. Liu J, Lin H, McIntosh H: Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat 8:358-366, 2001
13. Jadad AR, Moore A, Carroll D, et al.: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1-12, 1996
14. Leelarasamee A, Trakulsomboon S, Maunwongyathi P, Somanabandhu A, Pidetcha P, Matrakool B, Lebnak T, Ridthimat W, Chandanayingyong D: Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers. Lancet 335:1600-1601, 1990
15. Wang M, Zhou HB, Zhao GI, Zhao S, Mai K: Phyllanthus amarus cannot eliminate HBsAg in chronic B virus infection. Hepatology 21:22-24, 1991
16. Berk L, de Man RA, Schalm SW, Labadie RP, Heijtink RA: Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed. J Hepatol 12:405-106, 1991
17. Thamlikitkul V, Wasuwat S, Kanchanapee P: Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers. J Med Assoc Thai 74:381-385, 1991
18. Milne A, Hopkirk N, Lucas CR, Waldon J, Foo Y: Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. NZ Med J 107:243, 1994
19. Luper S: A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 3:410-421, 1998
20. Feher J, Lang I, Nekam KJ, Gergely P, Muzes G: In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai Exp Clin Med 15:129-134, 1990
21. Campos R, Garrido A, Guerra R, Valenzuela A: Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 55:417-419, 1989
22. Pietrangelo A, Borrella F, Casalgraudi G, et al.: Antioxidant activity of slilybin in vivo during long-term iron overload in rats. Gastroenterology 109:1941-1949, 1995
23. Boigk G, Stroedter I, Herbst H, Waldschmidt J, Riecken EO, Schuppan D: Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643-649, 1997
24. Tuchweber B, Sieck R, Trost W: Prevention of silybin of phalloidin induced acute hepatoxicity. Toxicol Appl Pharmacol 51:265-275, 1979
25. Faulstich H, Jahn W, Wieland T: Silybin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung 30:452-154, 1980
26. Jacobs BP, Dennehy C, Ramirej G, Sapp J, Lawrence VA: Milk thistle for the treatment of liver diseases: a systematic review and meta-analysis. Am J Med 113:506-515, 2002
27. Seef LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH: Complementary and alternative medicine in chronic liver disease. Hepatology 34:595-603, 2001
28. van Rossum TG, Vulto AG, de Man RA, Browner JT, Schalm SW: Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment pharmacol Ther 12:199-205, 1998
29. Yoshikawa M, Matsui Y, Kawamoto H, et al.: Effects of glycyrrhizin on immune mediated cytotoxicity. J Gastroenterol Hepatol 12:243-247, 1997
30. Miyaji C, Miyakawa R, Watanabe H, Kawamura H, Abo T: Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin. Int Immunopharmacol 2:1079-1086, 2002
31. Shiki Y, Shinai K, Satto Y, Yoshida S, Mosi Y, Wakashin M: Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrance antibody. J Gastroenterol Hepatol 7:12-16, 1992
32. Abe N, Ebina T, Ishida N: Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 26:535-539, 1982
33. Abe Y, Ueda T, Kato T, Kohli Y: Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho 52:1817-1822, 1994
34. Zhang L, Wang B: Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res 24:220, 2002
35. Miyake K, Tango T, Ota Y, et al.: Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis. J Gastroenterol Hepatol 17:198-204, 2002
36. Iino S, Tango T, Matsushima T, Toda G, Miyake K, Hino K, Kumada H, Yasuda K, Kuroki T, Hirayama C, Suzuki H: Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res 19:31-10, 2001
37. Kumada H: Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 62 (Suppl 1):94-100, 2002
38. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500, 1997
39. Acharya SK, Dasarathy S, Tandon A, Joshi YK, Tandon BN: A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res 98:69-74, 1993
40. Tandon A, Tandon BN, Bhujwala RA: Clinical spectrum of acute sporadic hepatitis E and possible benefit of glycyrrhizin therapy. Hepatol Res 23:55-61, 2002
41. Acharya SK, Dasarathy S, Panda SK, Joshi YK: Parenteral glycyrrhozin therapy (Stronger Neominophegen C) in patients with subacute hepatic failure (SHF), chronic hepatitis (CH) and cirrhosis with activity. Final report on the ICMR Force Project, Apr 4, 1992, Mar 31, 1997
42. Tandon BN, Joshi YK, Acharya SK: Subacute liver failure. Natl Med J India 1:124-127, 1988
43. Anand AC, Seth AK, Nagpal A, Varma PP, Gadela SR, Baliga KV, Chopra GS: Ribavirin plus glycyrrhizin is more effective than ribavirin monotherapy in renal allograft recipients with chronic hepatitis C (Abstr). Indian J Gastroenterol 23:S7, 2004
44. Takeda R, Morimoto S, Uchida K, Nakai T, Miyamoto M, Hashiba T, Yoshimitsu K, Kim KS, Miwa U: Prolonged pseudoaldosteronism induced by glycyrrhizin. Endocrinol Japan 26:541-547, 1979
45. Epstein M, Espiner E, Donald R, Hughes H: Effects of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects. Br Med J 1:488-490, 1977
46. Sandhir R, Gill KD: Hepatoprotective effects of Liv 52 on ethanol induced liver damage in rats. Indian J Exp Biol 37:762-766, 1999
47. Pandey S, Gujrati VR, Shanker K, Singh N, Dhawan KN: Hepato protective effect of Liv-52 against CC14 induced lipid peroxidation in liver of rats. Indian J Exp Biol 32:674-675, 1994
48. Gopumadhavan S, Jagadeesh S, Chauhan BL, Kulkarni RD: Protective effect of Liv 52 on alcohol-induced fetotoxicity. Alcohol Clin Exp Res 17:1089-1092, 1993
49. Roy A, Soni GR, Kolhapure RM, Karnik UR, Patki PS: Down regulation of tumour necrosis factor activity in experimental hepatitis by a herbal formulation, Liv 52. Indian J Exp Biol 32:694-697, 1994
50. Chauhan BL, Kulkarni RD: Effect of Liv 52, an herbal preparation, on absorption and metabolism of ethanol in humans. Eur J Clin Pharmacol 40:189-191, 1991
51. Fleig WW, Morgan MY, Holzer MA, European Multicenter Study Group: The ayurvedic drug Liv 52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double blind, placebo controlled clinical trial. J Hepatol 26 (Suppl 1):127, 1997 (abstr)
52. de Silva HA, Saparamadu PA, Thabrew MI, Pathmeswaran A, Fonseka MM, de Silva HJ: Liv 52 in alcoholic liver disease: a prospective, controlled trial. J Ethnopharmacol 84:47-50, 2003